File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/2047-9158-2-19
- Scopus: eid_2-s2.0-84884190046
- WOS: WOS:000215872400018
Supplementary
- Citations:
- Appears in Collections:
Article: Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease
Title | Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease |
---|---|
Authors | |
Keywords | Disease-modification Monoamine oxidase-B inhibitors Neuroprotection Parkinson's disease Rasagiline Selegiline |
Issue Date | 2013 |
Citation | Translational Neurodegeneration, 2013, v. 2, n. 1, article no. 19 How to Cite? |
Abstract | There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B (MAOB) inhibitors. They have been studied for their potential disease-modifying effects in Parkinson's disease (PD) for over 20 years in various clinical trials. This review provides a summary of the clinical trials and discusses the implications of their results in the context of disease-modification in PD. Earlier clinical trials on selegiline were confounded by symptomatic effects of this drug. Later clinical trials on rasagiline using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims of this strategy remain elusive due to obstacles, some of which may be insurmountable. © 2013 Teo and Ho; licensee BioMed Central Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/336119 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Teo, Kay Cheong | - |
dc.contributor.author | Ho, Shu Leong | - |
dc.date.accessioned | 2024-01-15T08:23:38Z | - |
dc.date.available | 2024-01-15T08:23:38Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Translational Neurodegeneration, 2013, v. 2, n. 1, article no. 19 | - |
dc.identifier.uri | http://hdl.handle.net/10722/336119 | - |
dc.description.abstract | There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B (MAOB) inhibitors. They have been studied for their potential disease-modifying effects in Parkinson's disease (PD) for over 20 years in various clinical trials. This review provides a summary of the clinical trials and discusses the implications of their results in the context of disease-modification in PD. Earlier clinical trials on selegiline were confounded by symptomatic effects of this drug. Later clinical trials on rasagiline using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims of this strategy remain elusive due to obstacles, some of which may be insurmountable. © 2013 Teo and Ho; licensee BioMed Central Ltd. | - |
dc.language | eng | - |
dc.relation.ispartof | Translational Neurodegeneration | - |
dc.subject | Disease-modification | - |
dc.subject | Monoamine oxidase-B inhibitors | - |
dc.subject | Neuroprotection | - |
dc.subject | Parkinson's disease | - |
dc.subject | Rasagiline | - |
dc.subject | Selegiline | - |
dc.title | Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1186/2047-9158-2-19 | - |
dc.identifier.scopus | eid_2-s2.0-84884190046 | - |
dc.identifier.volume | 2 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | article no. 19 | - |
dc.identifier.epage | article no. 19 | - |
dc.identifier.eissn | 2047-9158 | - |
dc.identifier.isi | WOS:000215872400018 | - |